Navigation Links
Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Date:2/1/2008

Board-Certified Regulatory Affairs Professional Brings More Than Two

Decades of Pharmaceutical, Regulatory Agency and Research Experience

CINCINNATI, Feb. 1 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the hiring of Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality. Dr. Tripathi will provide additional leadership to the Regulatory Affairs Brand, overseeing the multi-functional global regulatory group consisting of approximately 450 personnel. He will focus on driving growth in the company's regulatory brand, which includes strategic clinical development planning, regulatory consulting and submissions, clinical trial regulatory affairs, nonclinical consulting, Chemistry, Manufacturing and Controls (CMC) development, medical writing and pharmacovigilance/safety services.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

"We are thrilled to have someone with Satish's background and experience as part of our regulatory leadership team," said Melanie Bruno, PhD, Vice President, Global Regulatory Affairs, Quality and Safety. "His ability to analyze the regulatory complexities of drug development and fashion a market positioning strategy to help ensure commercial success will provide a wonderful resource to Kendle's customers."

Dr. Tripathi served most recently as the Director of Worldwide Regulatory Strategy at Pfizer (formerly Pharmacia). Prior to that, he was a Director of Global Regulatory Affairs at the Biosciences Division of Baxter Healthcare Corporation in charge of all global regulatory submissions within the Recombinant Strategic Business Unit. While at the U.S. Food and Drug Administration, Dr. Tripathi served as a Pharmacology and Toxicology Reviewer with an emphasis on oncology and pulmonary products.

Dr. Tripathi earned his doctorate from the University of Glasgow in Scotland, his Master of Philosophy from Bhopal University in India and bachelor's and master's degrees from Jiwaji University at Gwalior, India. His post-doctoral fellowships include the Massachusetts Institute of Technology, Emory University Medical School and the Medical College of Wisconsin.

Dr. Tripathi will be based in Kendle's Chicago office.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites and named "Best CRO" for the second consecutive year by leading global pharmaceutical publication Scrip.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the Wachovia 2008 Healthcare Conference
2. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
3. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
4. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
5. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
6. Kendle to Present at the UBS Global Life Sciences Conference
7. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
8. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
10. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
11. Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... National executive ... leader with extensive assay development and biomarker expertise, as VP of Scientific Affairs ... CRO specializing in bio-analytical assay development and sample testing services. The organization acts ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... discovery of antibody therapeutics from millions-diverse immune repertoires, announces launch of its new ... Diego, California. Dave Johnson, PhD, CEO of GigaGen, will present on Surge at ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... development reported today that it is launching two new additions of its award-winning ... demonstrating new capabilities at the DIA 2017 Annual Meeting in Chicago, IL, June ...
(Date:6/19/2017)... ... 2017 , ... A colony of healthy honey bees is like a superorganism--individual ... and nectar containing nutrients necessary for growth and survival. Better nutrition gives the colony ... point to a decline in honey bee health. Sick and weakened bees diminish the ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):